Development of a novel recombinant adenovirus containing gfp-zeocin fusion expression cassette for conditional replication in p53-deficient human tumor cells

Journal of Virological Methods

Volumn 117, Issue 2, 2004, Pages 129-136

  Hu, Baoli ^a   Joshua, Mallam Nock ^a   Dong, Changyuan ^b   Qi, Yipeng ^a  

^a WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Cancer gene therapy; E1B defective adenovirus; GFP; Replicative adenoviral vector; Zeocin gene

Indexed keywords

ADENOVIRUS VECTOR; BIOLOGICAL MARKER; E1B PROTEIN; GENE PRODUCT; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; ZEOCIN;

ARTICLE; BLADDER; CONTROLLED STUDY; CYTOLYSIS; EUKARYOTE; FIBROBLAST; GENE CONSTRUCT; GENE EXPRESSION; GENE FUSION; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROKARYOTE; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; TUMOR CELL; VIRUS REPLICATION;

ADENOVIRIDAE; BLEOMYCIN; CELL LINE, TUMOR; CLONING, MOLECULAR; CYTOMEGALOVIRUS; GENES, P53; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MICROSCOPY, FLUORESCENCE; MUTAGENESIS, INSERTIONAL; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; EUKARYOTA; PROKARYOTA;

EID: 1642368937     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2004.01.018     Document Type: Article

References (28)

1. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
2. Calmels T., Parriche M., Burand H.et al. High efficiency transformation of Tolypocladium geodes conidiospores to phleomycin resistance. Curr. Genet. 20:1991;309-314.
3. Curiel D.T. The development of conditionally replicative adenoviruses for cancer therapy. Clin. Cancer Res. 6:2000;3395-3399.
4. Drocourt D., Calmels T., Reynes J.P.et al. Cassette of the Streptoalloleteichus hindustanus ble to phleomycin resistance. Nucleic Acids Res. 18:1990;4009.
5. Erlwein O., Buchholz C.J., Schnierle B.S. The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus. J. Gen. Virol. 84(Pt. 2):2003;369-373.
6. Gomez-Navarro J., Curiel D.T., Douglas J.T. Gene therapy for cancer. Eur. J. Cancer. 35:1999;867-885.
7. Habib N.A., Mitry R., Seth P.et al. Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther. 9(8):2002;651-654.
8. Hall A.R., Dix B.R., O'Carroll S.J., Braithwaite A.W. p53-dependent cell eath/apoptosis is required for a productive adenovirus infection. Nat. Med. 4:1998;1068-1072.
9. Heise C., Kirn D.H. Replication-selective adenoviruses as oncolytic agents. J. Clin. Invest. 105:2000;847-851.
10. Heise C., Hermiston T., Johson L., Brooks G., Sampson-Johannes A., Williams A., Hawkins L., Kirn D. Adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6:2000;1134-1139.
11. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tuor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3:1997;639-645.
12. Hollstein M., Sidransy D., Vogelstein B., Harris C.C. P53 mutations in human cancer. Science. 253:1991;49-53.
13. Howe J.A., Demers G.W., Johnson O.E., Neugebauer S.E., Perry S.T., Vaillancourt M.T., Faha B. Evaluation of E1-mutant adenoviruses as conditionally replicating agent for cancer therapy. Mol. Ther. 2:2000;485-495.
14. John W., Andy J.B., Mark J.P., Subba R.P. Studies of the nucleopolyhedrovirus infection process in insect cells b using the green fluorescent protein as a reporter. J. Virol. 2:1998;3377-3382.
15. Kirn D., Hermiston T., McCormick F. ONYX-015: clinical date are encouraging. Nat. Med. 4:1998;1341-1342.
16. Lane D.P. Killing tumor cells with viruses - a question of specificity. Nat. Med. 4:1998;1012-1013.
17. Laura G.L., Adam A.L. Use of green fluorescent protein to monitor the survival of genetically engineered bacteria in aquatic environments. Appl. Environ. Microbiol. 62:1996;3486-3488.
18. Levine A.J., Momand J., Finlay C.A. The p53 tumor suppressor gene. Nature. 351:1991;453-456.
19. Norman, K.L., Farassati, F., Lee, P.W., 2001. Oncolytic viruses and cancer therapy. Cytokin Growth Factor Rev. 12, 271-282.
20. Oh J., Julias J.G., Ferris A.L., Hughes S.H. Construction and characterization of a replication-competent retroviral shuttle vector plasmid. J. Virol. 76(4):2002;1762-1768.
21. Perez L., Tiraly G., Kallerhoff J.et al. Phleomycin resistance as a dominant marker for plant cell transformation. Plant Mol. Biol. 13:1989;365-373.
22. Rothmann T., Hengstermann A., Whitaker N.T., Schettner M., Zur H.H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:1998;9470-9478.
23. Sambrook, J., Fristch, E.F., Maniatis, T., 1989. Molecular Cloning: A Laboratory Manual, second ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
24. Seth, P., Katayose, Y., Rakkar, A.N.S., 1999. Adenoviral vectors for cancer gene therapy. In: Seth, P. (Ed.), Adenovirus: Basic Biology to Gene Therapy. Landes, Austin, TX, pp. 103-120.
25. Southern E.M. Detection of specific sequences among NDA fragments separated by gel electrophoresis. J. Mol. Biol. 98:1975;503.
26. Turnell A.S., Grand R.T., Gallimore P.H. The replicative capacities of large E1B-null group A and C adenoviruses are independent of host cell p53 status. J. Virol. 73:1999;2074-2083.
27. Zhu F-X., Yi-Peng Q., Yong-Xiu H.et al. A baculovirus vector derived from immediately early gene promoter of Autographa californica nuclear polyhedrosis virus. J. Virol. Methods. 62:1996;71-79.
28. Zylka, M.J., Schnapp, B.J., 1996. Optimized filter set and viewing conditions for the S65T mutant of GFP in living cells. Biotechniques 21 (2), 220-1, 224-6.